Trials / Completed
CompletedNCT00276341
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis
Efficacy of EGb 761® 120mg Twice a Day Versus Placebo on Cognitive Impairment in Patients With Multiple Sclerosis. A Randomised, Double-blind, Multicentre, Parallel Groups Placebo Controlled Phase III Study.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the use of EGb 761 by patients with Relapsing-Remitting Multiple Sclerosis is effective in improving cognition, when compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EGb 761® (Tanakan®) |
Timeline
- Start date
- 2003-08-26
- Completion
- 2005-12-08
- First posted
- 2006-01-13
- Last updated
- 2024-03-07
Locations
30 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00276341. Inclusion in this directory is not an endorsement.